oxybutynin has been researched along with levonorgestrel in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 20 (86.96) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bodmeier, R; Fussnegger, B; Schulz, M | 1 |
| Cecchini, R; Gold, MA; Land, SR; Murray, PJ; Sucato, GS | 1 |
| Lidegaard, O; Løkkegaard, E; Nielsen, LH; Skovlund, CW | 1 |
| Banga, AK; Jain, P | 1 |
| Cannegieter, SC; Helmerhorst, FM; Lijfering, WM; Roach, RE; Rosendaal, FR; van Hylckama Vlieg, A | 1 |
| Archer, DF; Foegh, M; Rubin, A; Stanczyk, FZ | 2 |
| Bai, Y; Banga, AK; Kydonieus, A; Sachdeva, V | 1 |
| Heger-Mahn, D; Junge, W; Merz, M; Trummer, D | 1 |
| Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR; Portman, D; Rubin, A; Westhoff, CL | 1 |
| Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR | 1 |
| Bangerter, K; Kroll, R; Lynen, R; Merz, M | 1 |
| Archer, DF; Foegh, M; Kaunitz, AM; Mishell, DR; Portman, D; Westhoff, CL | 2 |
| Rome, ES; Strandjord, SE | 1 |
| Nisihara, R; Sgarbi, F; Wandresen, G | 1 |
| Mofidfar, M; Prausnitz, MR | 1 |
| Mofidfar, M; O'Farrell, L; Prausnitz, MR | 1 |
| Archer, J; Madden, T; Montoya, MN; Peipert, JF; Schultheis, P; Zhao, Q | 1 |
4 review(s) available for oxybutynin and levonorgestrel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Monthly Periods--Are They Necessary?
Topics: Adolescent; Contraceptive Devices, Female; Contraceptives, Oral, Hormonal; Female; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Menstruation; Menstruation Disturbances; Periodicity; Progestins; Transdermal Patch | 2015 |
Management of contraceptives and menstrual complaints in patients with Down syndrome.
Topics: Contraception; Contraceptive Agents, Female; Contraceptive Devices, Female; Contraceptives, Oral, Hormonal; Down Syndrome; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Menstruation Disturbances; Progesterone; Transdermal Patch | 2019 |
Twirla - a new contraceptive patch.
Topics: Contraceptive Agents, Hormonal; Estradiol; Female; Humans; Levonorgestrel; Transdermal Patch | 2021 |
8 trial(s) available for oxybutynin and levonorgestrel
| Article | Year |
|---|---|
Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
Topics: Adhesives; Adolescent; Adult; Contraceptives, Oral, Combined; Cross-Over Studies; Equipment Failure; Ethinyl Estradiol; Exercise; Female; Hot Temperature; Humans; Humidity; Immersion; Levonorgestrel; Middle Aged; Transdermal Patch; Water | 2013 |
Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
Topics: Abdomen; Adult; Buttocks; Cohort Studies; Contraceptive Agents, Female; Cross-Over Studies; Drug Combinations; Ethinyl Estradiol; Feasibility Studies; Female; Half-Life; Headache; Humans; Incidence; Levonorgestrel; Nausea; Pruritus; Skin Absorption; Thorax; Transdermal Patch; United States; Young Adult | 2013 |
Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomize
Topics: Adolescent; Adult; Contraceptives, Oral, Combined; Cross-Over Studies; Drug Administration Schedule; Ethinyl Estradiol; Female; Hemostasis; Humans; Levonorgestrel; Norpregnenes; Patient Compliance; Prothrombin Time; Transdermal Patch; Treatment Outcome; Young Adult | 2013 |
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
Topics: Adolescent; Adult; Body Mass Index; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; Ethnicity; Female; Humans; Levonorgestrel; Obesity; Patient Compliance; Pregnancy; Transdermal Patch; Treatment Outcome; Uterine Hemorrhage; Young Adult | 2014 |
Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Topics: Adolescent; Adult; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Drug Combinations; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Norgestrel; Obesity; Patient Outcome Assessment; Transdermal Patch; Young Adult | 2015 |
Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
Topics: Adolescent; Adult; Amenorrhea; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Double-Blind Method; Drug Combinations; Estrogens; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Menorrhagia; Menstrual Cycle; Metrorrhagia; Norpregnenes; Patient Dropouts; Progestins; Transdermal Patch; United States; Young Adult | 2015 |
Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
Topics: Adolescent; Adult; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Patient Compliance; Reproducibility of Results; Self Report; Transdermal Patch; Young Adult | 2015 |
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.
Topics: Adhesiveness; Adolescent; Adult; Contraceptives, Oral, Combined; Dermatitis, Contact; Drug Combinations; Ethinyl Estradiol; Female; Humans; Incidence; Levonorgestrel; Research Personnel; Transdermal Patch; Young Adult | 2015 |
11 other study(ies) available for oxybutynin and levonorgestrel
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Influence of adsorbents in transdermal matrix patches on the release and the physical state of ethinyl estradiol and levonorgestrel.
Topics: Administration, Cutaneous; Adsorption; Contraceptive Agents, Female; Crystallization; Delayed-Action Preparations; Drug Compounding; Estrogens; Ethinyl Estradiol; Humans; Levonorgestrel; Molecular Weight; Particle Size; Povidone; Solubility; Transdermal Patch; Water | 2011 |
Adolescents' experiences using the contraceptive patch versus pills.
Topics: Adolescent; Affect; Contraceptive Agents, Female; Contraceptives, Oral; Estrogens; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Longitudinal Studies; Menstruation; Norgestrel; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires; Transdermal Patch; Young Adult | 2011 |
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
Topics: Adolescent; Adult; Anticoagulants; Contraceptive Agents, Female; Contraceptive Devices, Female; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Denmark; Drug Implants; Epidemiologic Methods; Female; Humans; Levonorgestrel; Middle Aged; Norgestrel; Transdermal Patch; Venous Thrombosis; Young Adult | 2012 |
Induction and inhibition of crystallization in drug-in-adhesive-type transdermal patches.
Topics: Contraceptives, Oral, Synthetic; Crystallization; Drug Storage; Excipients; Levonorgestrel; Poloxamer; Povidone; Solubility; Temperature; Transdermal Patch | 2013 |
The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy.
Topics: Administration, Cutaneous; Age Factors; Aged; Case-Control Studies; Contraceptives, Oral, Hormonal; Desogestrel; Estradiol; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Levonorgestrel; Logistic Models; Medroxyprogesterone Acetate; Middle Aged; Netherlands; Norethindrone; Norethindrone Acetate; Odds Ratio; Postmenopause; Progestins; Risk Assessment; Risk Factors; Sex Factors; Transdermal Patch; Venous Thrombosis | 2013 |
Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies.
Topics: Adhesives; Animals; Contraceptives, Oral, Synthetic; Crystallization; Desogestrel; Excipients; Levonorgestrel; Male; Mineral Oil; Pyrrolidines; Rats; Rats, Hairless; Reproducibility of Results; Skin Absorption; Solubility; Transdermal Patch; Vinyl Compounds | 2013 |
Electrospun Transdermal Patch for Contraceptive Hormone Delivery.
Topics: Contraceptive Agents; Drug Delivery Systems; Levonorgestrel; Microscopy, Electron, Scanning; Mineral Oil; Polyesters; Spectroscopy, Fourier Transform Infrared; Thermogravimetry; Transdermal Patch | 2019 |
Pharmaceutical jewelry: Earring patch for transdermal delivery of contraceptive hormone.
Topics: Animals; Contraceptive Agents, Female; Drug Delivery Systems; Jewelry; Levonorgestrel; Rats, Hairless; Skin; Skin Absorption; Swine; Transdermal Patch | 2019 |
Contraception and ectopic pregnancy risk: a prospective observational analysis.
Topics: Cohort Studies; Contraceptive Agents, Female; Contraceptive Devices, Female; Contraceptives, Oral; Delayed-Action Preparations; Drug Implants; Female; Humans; Intrauterine Devices, Copper; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Pregnancy; Pregnancy, Ectopic; Proportional Hazards Models; Prospective Studies; Transdermal Patch | 2021 |